StockNews.AI
ERNA
StockNews.AI
119 days

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

1. Ernexa (ERNA) presents data on ERNA-101 at AACR Annual Meeting 2025. 2. ERNA-101 targets ovarian tumors using engineered cell therapies. 3. Data presentation emphasizes potential to improve treatments for advanced cancer. 4. CEO highlights the promise of cell therapy reshaping cancer treatment. 5. Conference attendees can engage with the study's authors and executives.

6m saved
Insight
Article

FAQ

Why Bullish?

The presentation at AACR 2025 showcases ERNA-101's potential, comparable to previous successful therapies like CAR-T. A strong presentation can increase investor confidence similar to other biotech breakthroughs.

How important is it?

The presentation has direct implications on ERNA's clinical progress and investor perception, making it highly relevant.

Why Short Term?

Immediate interest from investors during and after AACR could drive short-term price increases, as seen historically after similar conferences.

Related Companies

MD AndersonCAR-TGILD
CAMBRIDGE, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that new data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The study explored the technology behind Ernexa’s lead cell therapy product, ERNA-101, which uses specially engineered cells to deliver treatment directly to ovarian tumors. By secreting immune-stimulating cytokines, this cell therapy treatment aims to reshape the tumor microenvironment and enhance anti-tumor immune responses, fighting off the cancer. The study was led by Michael Andreeff, M.D., Ph.D., from The University of Texas MD Anderson Cancer Center. “We believe ERNA-101 represents a powerful new way to engage the immune system against difficult-to-treat cancers like ovarian cancer,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “This study reinforces the promise of our treatments and their potential to reshape the future of cell therapy. We aim to offer hope for patients with advanced ovarian cancer, who often face limited treatment options and poor long-term outcomes.” Details of the poster presentation session include:Session Category: ImmunologySession Title: Local Treatments, Novel Tools, and Delivery Systems to Manipulate Tumor ImmunityDate and Time: Monday, April 28, 2025 at 2:00–5:00 pm CDTLocation: Poster Section 37Poster Board Number: 12Published Abstract Number: 3473 Conference attendees can learn the results of the study at the presentation. They can also meet with Ernexa’s Chief Scientific Officer, Robert Pierce, M.D., and the study’s authors. About ErnexaTherapeutics Ernexa Therapeutics (Nasdaq: ERNA) is developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune disease. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting. Ernexa is developing two highly innovative cell therapy products, both currently in preclinical stages. ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. ERNA-102 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer. For more information, visit www.ernexatx.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law. Media & Investor Relations Contact investors@ernexatx.com

Related News